您现在的位置: 首页> 研究主题> 移植物抗白血病

移植物抗白血病

移植物抗白血病的相关文献在1995年到2022年内共计74篇,主要集中在肿瘤学、临床医学、基础医学 等领域,其中期刊论文70篇、会议论文1篇、专利文献325576篇;相关期刊41种,包括医药与保健、中国实验血液学杂志、国际输血及血液学杂志等; 相关会议1种,包括第57届美国血液年会等;移植物抗白血病的相关文献由224位作者贡献,包括高清平、邹萍、吴德沛等。

移植物抗白血病—发文量

期刊论文>

论文:70 占比:0.02%

会议论文>

论文:1 占比:0.00%

专利文献>

论文:325576 占比:99.98%

总计:325647篇

移植物抗白血病—发文趋势图

移植物抗白血病

-研究学者

  • 高清平
  • 邹萍
  • 吴德沛
  • 孙自敏
  • 居小萍
  • 徐杨
  • 王健民
  • 胡文兵
  • 艾辉胜
  • 赵刚

移植物抗白血病

-相关会议

  • 期刊论文
  • 会议论文
  • 专利文献

搜索

排序:

年份

    • 吴蔚冰; 常英军
    • 摘要: 尽管单倍型相合造血干细胞移植(Haplo-HSCT)治疗恶性血液病获得了与人类白细胞(HLA)相合同胞供者移植(MSDT)相当的疗效,但由于MSDT较Haplo-HSCT具有造血和免疫重建快、感染发生率低等优点,HLA相合同胞供者仍是国内外学者公认的首选供者来源.近年来,部分研究证实Haplo-HSCT治疗移植前微小残留病(MRD)阳性的急性白血病(AL)等亚组人群较MSDT具有更强的移植物抗白血病作用,文章就移植前MRD阳性AL等恶性血液病亚组人群的最佳供者选择进行了讨论,并提出应该首选单倍型相合供者,而不是HLA相合同胞供者.
    • 摘要: Wilkinson等人发现受体树突细胞(DC)分泌的IL-6启动了这种细胞因子的系统失调。靶向敲除T细胞中的IL-6受体(IL-6R)后,抑制DC驱动的经典信号可消除致病性供体Th17/Th22细胞的分化,患者从而获得长期存活。移植后,供体DC承担同样的角色,维持经典的IL-6信号依赖性的GVHD反应。此外,移植后的群集信号通路并不活跃,但用sgp130Fc抑制反式信号通路可促进发生严重的慢性皮肤GVHD。后者是多功能性Th22细胞扩增过度的结果,耗竭IL-22或抑制IL-6R可逆转这一结果。重要的是,抑制IL-6经典信号并不影响移植物抗白血病的作用。
    • 党四华; 刘文; 邹萍; 刘芩; 仲照东; 游泳; 崔杰克; 蒋林; 沈娜; 谢荣; 周姝
    • 摘要: Objective To observe the anti-relapse and anti-graft versus host disease (GVHD) effects and side effects of ruxolitinib on patients who have relapsed leukemia after allo-hematopoietic stem cell transplantation (HSCT).Methods The clinical data of four patients sufferring from relapsed leukemia were collected and analyzed retrospectively.Three cases had a positive gene and 1 case had a extramedullary recurrence.All of them had serious GVHD involving multiparts,as the result of attenuating immunosuppressant aggressively.One case had central nervous system leukemia before allo-HSCT.Those patients were treated with ruxolitinib,according to the degree of GVHD,the treatment strategy and curative effect of GVHD,and the residual condition of original leukemia.Then,the degree of GVHD,the residual condition of original leukemia and the side effects of ruxolitinib were revaluated once a month after taking ruxolitinib.Results One case achieved completer remission (CR) and there partial remission (PR) in consideration of GVHD.Up to date,2 cases had no relapse in any level and 2 cases replased according to any of the results related to bone marrow aspiration.Conclusion Ruxolitinib is effective in patients with GVHD after allo-HSCT and doesn't influence GVL effect or increase the risk of relapse at the same time.Ruxolitinib doesn't have obvious side effects when treating GVHD.%目的 观察芦可替尼在造血干细胞移植后抗移植物抗宿主病(GVHD)和抗白血病复发的平衡作用及其不良反应.方法 回顾性收集、分析4例造血干细胞移植后因复发而减停免疫抑制剂出现GVHD受者的临床资料,根据GVHD程度、GVHD治疗策略和疗效、疾病残留情况,给予芦可替尼治疗;依据美国国立卫生研究院(NIH)慢性GVHD评分及NIH治疗反应评估标准评价GVHD程度及疗效,依据骨髓细胞形态学、MRD、染色体、融合基因检查及外周血涂片、包块穿刺活检诊断原发病复发并评估其转归情况,依据常见不良反应事件评价标准(CTCAE) 3.0版评价芦可替尼治疗的不良反应.评估周期为每月1次.结果 经芦可替尼治疗后,原发病转归情况:3例基因阳性者2例全部转为阴性且随访至今持续阴性,其中1例最终出现细胞学复发,现仍存活,1例多次复发者接受治疗8个月后再次复发.GVHD缓解情况:4例受者均表现为持续部分缓解(PR).不良反应:4例受者均未观察到明显不良反应.结论 芦可替尼用于治疗HSCT后GVHD的疗效明显,在控制GVHD的过程中不影响移植物抗白血病(GVL)效应,未发生明显不良反应,体现了抗GVHD治疗和GVL效应之间的平衡.
    • 孙自敏
    • 摘要: 脐血已成为异基因造血干细胞移植中一个重要的干细胞来源.随着临床移植例数的增多和基础研究的进展,资料显示接受非血缘脐血移植(UCBT)患者移植后的复发率较低且慢性移植物抗宿主病(cGVHD)的发生率也很低,患者具有较高的无GVHD无复发生存率和较佳的生活质量.伴随着脐血移植技术的完善,UCBT的应用也逐渐扩大至非恶性血液病和一些老年患者的移植中,其将为这些患者提供一种新的治疗选择.本文对UCBT的现状作一综述.
    • 宣丽; 戴敏; 范志平; 黄芬; 周红升; 江千里; 许娜; 高雅; 孙竞
    • 摘要: Objective To explore the safety and effectiveness of sequential intensified conditioning regimen combined with graft-versus-1eukemia (GVL) induction in allogeneic hematopoietic stem cell transplantation (allo-HSCT) for refractory advanced acute lymphoblastic leukemia (ALL).Methods A total of 74 patients with refractory ALL,undergoing allo-HSCT from Jan.2005 to Dec.2014,were enrolled in this study.Intensified conditioning was:fludarabine + cytarabine plus total body irradiation + cyclophosphamide + etoposide.Cyclosporine A was withdrawn rapidly in a stepwise fashion if patients did not experience acute graft-versus-host disease (aGVHD) by day + 30 post-transplantation.Donor lymphocytes were infused in patients without grade Ⅱ or more than grade Ⅱ aGVHD by day + 60 post-transplantation.Results Except for one who died of infection and one who died of regimen-related toxicity (RRT),the remaining 72 patients achieved complete remission at the time of neutrophil reconstitution.The mortality of RRTs was 1.4% (1/74).The 5-year cumulative incidence of relapse post-transplantation was (29.2 ± 6.1)%.The 5-year non-relapse mortality was (30.4 ± 5.6) %.The 5-yesr overall and disease-free survival was (49.5 ± 5.9) % and (48.2 ± 5.9) % respectively.The 5-year leukemia relapse rate,overall and disease-free survival were similar between patients with B-cell ALL and T-cell ALL (P =0.929,P =0.652,P =0.691).Multivariate analysis revealed that donor lymphocyte infusion,chronic GVHD and bone marrow blasts on day 0 were independent prognostic factors for relapse and survival (P =0.043,P=0.026,P<0.001;P=0.045,P=0.029,P<0.001).Conclusion The strategy of sequential intensified conditioning combined with GVL induction could decrease the relapse rate and improve the survival for refractory ALL.%目的 探讨超强预处理异基因造血干细胞移植(allo-HSCT)联合移植物抗白血病(GVL)诱导策略治疗难治性未缓解急性淋巴细胞白血病(ALL)的安全性和有效性.方法 将2005年1月至2014年12月行allo-HSCT的74例难治性ALL患者纳入此研究.序贯超强预处理方案为氟达拉滨+阿糖胞苷+全身放疗+环磷酰胺+依托泊苷.GVL诱导策略包括:移植后第30天对未发生急性移植物抗宿主病(GVHD)者给予快速递减免疫抑制剂,至第60天未发生Ⅱ度或以上急性GVHD者给予供者淋巴细胞输注(DLI).结果 除2例在移植后1周内分别死于感染和预处理相关毒性外,其他受者均在粒系重建时获得完全缓解.预处理相关致死率为1.4%(1/74).白血病的5年复发率为(29.2±6.1)%,5年非复发死亡率为(30.4±5.6)%,5年总存活率(OS)和无病存活率(DFS)为(49.5±5.9)%和(48.2±5.9)%.B淋巴细胞ALL和T淋巴细胞ALL患者的5年复发率、OS和DFS无显著差异(P=0.929、P=0.652和P=0.691).DLI、慢性GVHD和移植0天骨髓幼稚细胞是移植后复发和生存的独立预后因素(P=0.043、P=0.026及P<0.001;P=0.045、P=0.029及P<0.001).结论序贯超强预处理allo-HSCT联合GVL诱导策略能降低难治性ALL复发率和提高受者的存活率.
    • 宣丽; 范志平; 张钰; 黄芬; 戴敏; 李勇华; 聂大年; 林东军; 江千里
    • 摘要: Objective To explore the therapeutic effects of sequential intensified conditioning regimen followed by graft-versus-leukemia (GVL) induction in allogeneic hematopoietic stem cell transplantation (allo-HSCT) for refractory advanced acute myeloid leukemia (AML).Methods A total of 72 patients with refractory AML undergoing allo-HSCT from May 2001 to June 2013 wcrc cnrolled in this prospective study.Intensified conditioning included fludarabine + cytarabine plus total body irradiation + cyclophosphamide + etoposide.Cyclosporine A was withdrawn rapidly in a stepwise fashion if patients who did not experience acute graft-versus-host disease (aGVHD) at Day + 30 post-transplantation.Donor lymphocytes were infused in patients without grade Ⅱ or more than grade Ⅱ aGVHD at Day + 60 posttransplantation.Results The median follow-up time was 655 (1-4 200) d post-transplantation.Except for one died of infection and one died of regimen-related toxicity (RRT),the other 70 patients achieved complete remission at the time of neutrophil reconstitution.The mortality of RRT was 1.4% (1/72).The 1-year cumulative incidence of aGVHD and 2-year incidence of chronic GVHD (cGVHD) posttransplantation were 60.7% ± 5.0% and 58.5% ±4.7%.The 5-year cumulative incidence of relapse posttransplantation was 29.6% ± 6.6%.The 5-year non-relapse mortality was 28.8% =6.0%.The 5-year overall and disease-free survival were 51.0% ± 6.5% and 49.9% ± 6.4%.Multivariate analysis revealed that donor lymphocyte infusion,cGVHD and bone marrow blasts at Day 0 were independent prognostic factors for relapse (HR (95 % CI):0.042 (0.007-0.688),0.009 (0.003-0.345),3.385 (1.451-7.899)) and survival(HR(95% CI):0.315 (0.146-0.621),0.416 (0.200-0.866),1.332 (1.158-1.533)).Conclusion The strategy of sequential intensified conditioning followed by GVL induction has an acceptable toxicity profile,and could decrease the relapse rate and improve the survival for refractory AML.%目的 探讨超强预处理异基因造血干细胞移植(allo-HSCT)伴随移植物抗白血病(GVL)诱导策略预防难治性未缓解急性髓系白血病(AML)移植后复发的有效性.方法 2001年5月至2013年6月于南方医科大学南方医院、广州军区总医院、中山大学附属第二医院和中山大学附属第三医院行allo-HSCT的72例难治性AML患者纳入此前瞻性研究.序贯超强预处理方案为氟达拉滨+阿糖胞苷+全身放疗+环磷酰胺+鬼臼乙甙.GVL诱导策略包括:对移植后30 d内未发生急性移植物抗宿主病(aGVHD)者予快速递减免疫抑制剂,移植后60 d内未发生Ⅱ度或以上aGVHD者予供者淋巴细胞输注(DLI).结果 移植后中位随访655(1 ~4 200)d.除2例在移植后1周内分别死于感染和预处理相关毒性外,其他患者均获得完全缓解.预处理相关致死率为1.4%(1/72).1年aGVHD和2年慢性GVHD(cGVHD)累积发生率为60.7%±5.0%和58.5%±4.7%.5年白血病累积复发率为29.6%±6.6%,5年非复发累积死亡率为28.8%±6.0%,5年累积总生存率和无病生存率为51.0%±6.5%和49.9%±6.4%.DLI、cGVHD和移植第0天(回输于细胞前)骨髓幼稚细胞数是移植后复发[HR(95% CI):0.042(0.007 ~0.688)、0.009(0.003 ~0.345)、3.385(1.451 ~7.899)]和生存[HR(95% CI):0.315(0.146 ~0.621)、0.416(0.200 ~0.866)、1.332(1.158 ~1 533)]的独立预后因素.结论 序贯超强预处理allo-HSCT伴随GVL诱导策略有可接受的移植相关毒性,能降低难治性AML复发率和提高其生存率.
    • 孙自敏
    • 摘要: 脐血已逐渐成为异基因造血干细胞移植治疗中的一个重要的干细胞来源.尽管移植相关病死率稍高,但由于复发率较低、移植后患者的生存质量较高,接受脐血移植患者的存活率与其他类型的造血干细胞移植相当.脐血移植技术的不断改善也给患者带来了更好的移植疗效.双份脐血移植克服了脐血细胞数量不足的缺陷,扩大了脐血移植在高体重的儿童和成人患者中的应用.而减低剂量预处理方案的脐血移植则为一些老年患者提供了新的治疗选择.
    • 张晓春; 郑晓敏; 陈诚; 李义德
    • 摘要: 目的:观察t (17; 19)-急性淋巴细胞白血病(ALL)细胞对肿瘤坏死因子(TNF)相关凋亡诱导配体(TRAIL)所介导的细胞毒的敏感性及可能机制,并探讨其临床意义.方法:以t(17; 19)-ALL细胞株4株、1例t (17; 19)-ALL患者骨髓标本为实验组,其他ALL细胞株28株为对照组.流式细胞术测定细胞表面TRAIL受体表达;重组人可溶性TRAIL (rhsTRAIL)作用后,3H-thymidine法测定其对细胞增殖的影响;FITC标记的Annexin-V染色及流式细胞术检测细胞早期凋亡;免疫印迹法观察细胞凋亡通路变化(caspase-8、Bia、caspase-3和PARP的表达).结果:t(17; 19)-ALL细胞表面死亡受体4(DR4)表达水平明显高于其他各组细胞株(P<0.05),死亡受体5 (DR5)表达水平高于MLL+-ALL细胞株(P<0.05),诱骗受体1(DcR1)和诱骗受体2 (DcR2)均呈阴性表达;rhsTRAIL浓度为100 μg·L-1时,t (17; 19)-ALL细胞抑制率接近100%,显著高于其他各组细胞株(P<0.05或P<0.01),该抑制作用在加入TRAIL中和抗体RIK-2及caspase广谱抑制剂z-VAD-fmk后被阻断;加入rhsTRAIL后,t(17; 19)-ALL细胞发生早期凋亡,其凋亡率明显高于对照组细胞株(P<0.05); rhsTRAIL作用2h内,caspase-8、Bid、caspase-3和PARP出现活化条带.结论:t (17; 19)-ALL细胞株对TRAIL高度敏感,并最终对移植物抗白血病(GVL)效应敏感,t (17; 19)-ALL患者为获得长期存活,应及早进行同种造血干细胞移植(allo-SCT).
    • 刘寿生
    • 摘要: 自1971年Thomas等首次报道造血干细胞移植(HSCT)能够使白血病患者长期存活以来,HSCT已成为恶性或难治性血液病最有效的根治性治疗方法之一.但移植物抗宿主病(GVHD)目前仍然是造成移植失败和移植相关死亡的主要因素.传统的GVHD防治策略,如免疫抑制剂的应用、去除供者T淋巴细胞,虽可一定程度降低GVHD的发生率及严重程度,但同时也削弱了移植物抗白血病(GVL)效应,使恶性肿瘤复发率增高.
    • 徐霖; 纳宁; 陈康; 曹开源; 袁广卿; 傅强; 朱蓓莉
    • 摘要: 目的:观察不成熟CD8α+树突状细胞(DC)体外经同种异基因白血病细胞全抗原冲击后的移植物抗白血病(GVL)效应.方法:C57BL/6(H-2b)小鼠的骨髓细胞以GM-CSF +IL-4 +SCF +Flt3L体外诱导不成熟CD8α+DC,第3 d加入0 mg/L、2.5 mg/L、5 mg/L、10 mg/L和20 mg/L BALB/c(H-2d)小鼠来源的同种异基因EL9611红白血病细胞抗原冲击,冲击后DC与同系(H-2b)T细胞按DC/T 1:1、2:1、4:1比例共培养,MTT法观察T细胞增殖情况,ELISA法检测上清中IFN-γ和IL-10的含量,LDH释放法检测T细胞对EL9611细胞的杀伤活性.以成熟DC为对照,观察同种异基因不成熟CD8α+DC体外对EL9611白血病细胞的GVL效应.结果:同种红白血病全抗原冲击后不成熟CD8α+DC可有效刺激同系T细胞增殖,作用随DC/T比例增加而增加,增殖效应在小剂量抗原(≤5 mg/L)冲击时更明显(P<0.05);Ag冲击后不成熟CD8α+DC刺激T细胞分泌IFN-γ和IL-10明显增高(P<0.05),IL-10的分泌与不成熟CD8α+DC发挥GVL效应存在一定的负相关关系,Ag冲击浓度较低而IL-10分泌少时,T细胞增殖活性较强.杀伤实验结果显示,白血病特异性T细胞对EL9611靶细胞的杀伤活性随抗原冲击浓度的增加而升高,浓度为2.5 mg/L时,杀伤率即可达90%,非特异性杀伤实验显示白血病特异性T细胞对同种异基因正常脾细胞的杀伤活性低于对照组(P<0.05),表明杀伤作用为抗原特异性杀伤,对正常细胞无明显杀伤.结论:经同种异基因白血病抗原冲击后不成熟CD8α+DC体外能刺激同系T细胞产生一定的GVL效应.%ATM: To observe the graft - versus - leukemia ( GVL ) effect of immature CD8α+ dendritic cells ( DC ) plus impulsing of allogeneic leukemia whole - cell antigen in vitro. METHODS: Bone marrow cells of C57BL/6( H - 2b ) mice were induced by GM - CSF +IL-4 + SCF + Flt3L in vitro to prepare immature CD8α+ DC. On day3, different doses of BALB/c( H - 2d ) - derived allogeneic EL9611 leukemia antigen at concentration series of of mg/L, 2. 5 mg/L, 5 mg/L, 10 mg/L and 20 mg/L were added. After impulsing, DCs were co - cultured with syngeneic T cells at DC/T ratio of 1 : 1, 2:1 or 4:1. Proliferation of the T cells was measured by MTT method. The concentrations of IFN - γ and IL - 10 in cultured supernatants were detected by ELISA. Cytotoxicity of T cells on EL9611 cells was measured by LDH releasing assay. Mature DC served as the control and in vitro GVL effect of allogeneic immature CD8α+ DC on EL9611 leukemia cells was observed. RESULTS: Immature CD8α+ DC plus impulsing of allogeneic leukemia antigen ef-fectively stimulated syngeneic T cell proliferation, which increased with DC/T ratio. The effect of proliferation was more obviously, especially in the presence of antigen at low dose ( ≤5 mg/L, P <0. 05 ). The secretions of IFN - y and IL - 10 in the T cells stimulated with antigen plus immature CD8α+ DC became higher significantly ( P < 0. 05 ). There was a certain negative correlation between the secretion of IL - 10 and the GVL effect of CD8α+ immature DC. When the concentration of impulsing antigen and IL - 10 secretion was low, T cell proliferation became higher. The results of cytotoxicity assay showed that the cytotoxicity activity of leukemia specific T cells on EL9611 target cells increased with the antigen concentration, and the killing rate reached 90% when the concentration of the antigen was 2. 5 mg/L. Non - specific cytotoxicity assay showed that cytotoxicity activity of leukemia specific T cells on allogeneic normal spleen cells was lower than that in control group ( P < 0. 05 ), indicating that it was a specific killing, and no obvious cytotoxicity to normal cells was observed. CONCLUSION: CD8α+immature DC plus impulsing of allogeneic leukemia antigen stimulates syngeneic T cells to generate GVL effect.
  • 查看更多

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号